scholarly journals Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Machiko Umemura ◽  
Goki Suda ◽  
Shihori Tsukamoto ◽  
Ko Ebata ◽  
Shinjiro Takahash ◽  
...  
Keyword(s):  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
On Demand ◽  
Large B Cell Lymphoma ◽  
First Case ◽  
Direct Acting ◽  
Large B Cell

Abstract Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.

scholarly journals Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report

2019 ◽  
Vol 18 ◽  
pp. 232595821882206
Author(s):  
Alyssa Gallipani ◽  
Agnes Cha ◽  
Leonard Berkowitz ◽  
Anjali Bakshi
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Concomitant Treatment ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

This report describes a case of concomitant treatment of advanced diffuse large B-cell lymphoma with chemoimmunotherapy along with direct-acting antivirals for hepatitis C virus in a patient coinfected with HIV. The patient tolerated gemcitabine, dexamethasone, cisplatin, and rituximab and achieved sustained virologic response after treatment with ledipasvir/sofosbuvir.

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

2020 ◽  
Vol 61 (9) ◽  
pp. 2122-2128 ◽  
Author(s):  
Michele Merli ◽  
Irene Defrancesco ◽  
Carlo Visco ◽  
Caroline Besson ◽  
Alice Di Rocco ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma

2019 ◽  
Vol 51 (5) ◽  
pp. 719-723 ◽  
Author(s):  
Vincenzo Occhipinti ◽  
Lucia Farina ◽  
Mauro Viganò ◽  
Marco Capecchi ◽  
Sara Labanca ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
Concomitant Therapy ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association?

2000 ◽  
Vol 79 (9) ◽  
pp. 530-532 ◽  
Author(s):  
I. Genvresse ◽  
E. Späth-Schwalbe ◽  
H. Meisel ◽  
O. Kaufmann ◽  
D. H. Krüger ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hepatitis C Virus Infection ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection

2021 ◽  
Vol 11 (9) ◽  
pp. 844
Author(s):  
Yu-Fen Tsai ◽  
Yi-Chang Liu ◽  
Ching-I Yang ◽  
Tzer-Ming Chuang ◽  
Ya-Lun Ke ◽  
...  
Keyword(s):  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
Performance Status ◽  
Poor Performance ◽  
B Cell Lymphoma ◽  
Liver Involvement ◽  
Poor Performance Status ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Background: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. Methods: A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. Results: A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivariate analysis, poor performance status (p < 0.001), advanced stage (p < 0.001), less chemotherapy cycles (p < 0.001), and the presence of liver toxicity (p = 0.001) contributed to poor OS in DLBCL. Among HCV-positive DLBCL, the severity of liver fibrosis was the main risk factor related to death. Conclusion: Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.

scholarly journals B-cell acute lymphoblastic leukemia as a secondary malignancy following diffuse large B-cell lymphoma

2019 ◽  
Vol 11 (2) ◽  
Author(s):  
Daria Gaut ◽  
Anthony Bejjani ◽  
Joshua Sasine ◽  
Gary Schiller
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
Lymphoblastic Leukemia ◽  
B Cell Lymphoma ◽  
Pcr Analysis ◽  
Secondary Malignancy ◽  
Large B Cell Lymphoma ◽  
First Case ◽  
Large B Cell

Secondary acute lymphoblastic leukemia (ALL) is a rare disease that has not been well characterized compared with secondary myelodysplastic syndrome or secondary acute myeloid leukemia. We present a report of two patients who developed ALL following complete remission of diffuse large B-cell lymphoma (DLBCL). The first case is more consistent with a therapy-related ALL as a PCR analysis of bone marrow aspirate revealed a distinct clone and the mixed-lineage leukemia gene rearrangement, commonly associated with exposure to topoisomerase II inhibitors. The second case is more consistent with clonal evolution given positive MYC and BCL2 fusion signals in the original diagnosis of DLBCL and the secondary ALL.

Sign in / Sign up

Export Citation Format

Share Document